New Hampshire Bulletin
18/11/2026 06:55

Commentary: NH shouldn’t confuse regulating dangerous kratom-labeled products with banning an entire plant

"Some of these products marketed as 'kratom' bear little resemblance to traditional botanical preparations, containing compounds not naturally present in the plant and, in some cases, acting exclusively on opioid receptors in the brain." (Photo by Michael Achterling/North Dakota Monitor)

Recently, there have been talks about New Hampshire once again debating how to address kratom, but this time the proposals seem considerably more sweeping. One proposal involves legislation that would classify kratom, the plant, as a Schedule I controlled substance. This would place it in the same legal category as heroin and other illicit drugs.

As an addiction psychiatrist with national expertise in kratom and its impact on clinical populations, I certainly see the concerns driving this proposal. A significant proportion of today’s marketplace consists primarily of highly concentrated, semi- and fully synthetic products labeled as “kratom,” which pharmacologically and safety-wise resemble nothing of the kratom plant itself. The kratom plant has been used for centuries in Southeast Asia without much concern, but the products we have here created legitimate public health concerns. 

Recognizing a problem and choosing the appropriate solution are two separate entities. As a state, we should be careful not to erroneously treat every product labeled “kratom” as pharmacologically equivalent, and most importantly not to assume that blanket prohibition is the most effective way to protect the public.

Here are several key considerations that should inform the development of any legislative approach.

The kratom market has evolved in recent years

Traditional kratom refers to the dried leaves of Mitragyna speciosa, a tropical tree native to Southeast Asia. Historically, leaves have been used for various remedies, to assist with pain management, enhance endurance, and as part of traditions and ritual ceremonies. Typical consumption involves either chewing the leaves or brewing them as a tea, or, to a lesser degree, smoking them. 

In the United States, early use largely involved powdered leaf consumed in capsules or mixed into beverages by those looking to self-manage various ailments, to get off illicit substances, or promote general well-being, among other reasons.

Over the years, manufacturers developed concentrated extracts, enhanced and even blended formulations that deliver increasingly potent doses, and have raised concerns about adverse effects.

Today, what we have available are semi- and fully synthetic compounds, highly concentrated 7-OH products and chemically modified derivatives. Some of these products marketed as “kratom” bear little resemblance to traditional botanical preparations, containing compounds not naturally present in the plant and, in some cases, acting exclusively on opioid receptors in the brain. These products should not automatically be treated as interchangeable by virtue of their shared marketing label.

Schedule I classification warrants careful examination

Schedule I classification is the most restrictive drug-control designation, and it carries significant consequences for possession, distribution, access and, most importantly, research. It also serves as an evidence-based determination that a substance has a “high potential for abuse and no currently accepted medical use.”

Comparing everything sold as “kratom” to opioids and calling it “gas station heroin” makes for a very catchy news headline and political sound bite, but it does not substitute for rigorous scientific and regulatory assessments.

A blanket classification may create unintended consequences for numerous individual consumers. Over the past decade of studying this botanical, I have encountered patients using botanical kratom preparations to self-manage pain, often being able to avoid opioid therapy, as well as to address other conditions for which FDA-approved treatments were ineffective or not tolerated. Making botanical kratom a Schedule I may prompt some of these individuals to turn to less regulated alternatives, seek products through illicit channels or substitute for other substances. For some consumers anecdotally using kratom for relapse prevention, this could mean losing a tool that they have found helpful in preventing a return to conventional opioids.

I am not making the argument that kratom should be used for the treatment of opioid use disorder, as a substitute for FDA-approved therapies or as a recommended therapeutic intervention for any condition. Rather, I suggest that policymakers should consider the real-world consequences of prohibition, which historically have included unintended substitution and reduced product oversight.

Other states are approaching kratom differently

It is important to recognize that we do not have to choose between unregulated retail sales and an overall blanket ban. Other states have implemented several regulatory models worth examining.

Last month, I was invited to be part of a panel in Rhode Island and had a chance to learn about how officials there are approaching kratom. After previously banning kratom, the state reversed course and in April of this year implemented the Rhode Island Kratom Act. The law established a tightly regulated marketplace to replace the outright ban.

Under this framework, the oversight is done by the Department of Health through its Center for Food Protection, which licenses and enforces requirements for manufacturers, distributors, importers and retailers. Sales to individuals younger than 21 are prohibited. Products sold must meet labeling and packaging requirements, as well as the state-established restrictions on how concentrated these can be, while also banning semi- and fully synthetic products. In addition, Rhode Island also imposes a 15% tax on the wholesale cost.

Since this was just implemented earlier this year, the overall efficacy and safety of this approach is too early to claim. What is important to emphasize here is the state has created a framework through which products, manufacturers and retailers can be identified, monitored and held accountable.

Other states have pursued variations of this approach, with most having enacted age restrictions, registration requirements and prohibitions on certain synthetic compounds. There are, of course, states such as Massachusetts that have taken a more restrictive approach, temporarily placing all forms of kratom, including botanical, under Schedule I.

We have an opportunity here to evaluate which policies actually serve the public and align with public health goals, rather than assume that the most restrictive policy is the most effective.

So, what does the research actually tell us?

A 2026 Centers for Disease Control and Prevention analysis revealed that between 2015 and 2025 there has been a 1,200% increase in kratom-related exposure reports. Unfortunately, the data do not establish that botanical kratom was responsible for these outcomes as the investigators could not reliably distinguish it from concentrated or chemically modified “kratom” products.

A separate 2026 observational study examined poison center-reported kratom exposures from 2010 through 2023 and compared states with different regulatory approaches. States with full kratom bans had lower reported exposure rates, severe outcomes, hospitalizations and healthcare utilization compared to states where kratom remained legal. This study found no statistically significant differences among states with consumer protection laws, local restrictions and states with unrestricted access.

This study does not establish that prohibition is superior, or that consumer protection laws reduce kratom-related harm. This data stems from poison center reports, which are highly variable in terms of reporting patterns, differences in enforcement and other state-level characteristics. What this study calls out for, however, is the need for better outcome data, and cautions against presenting regulation as an already proven solution. Rhode Island provides an opportunity to collect those data prospectively, and New Hampshire should learn from those outcomes as they become available.

New Hampshire needs a thoughtful approach

Earlier this year, Senate Bill 557 and other proposals attempted to address semi- and fully synthetic “kratom” products, but lawmakers failed to reach agreement. As we move forward, we need to make the distinction between botanical kratom and the increasingly potent derivatives.

As an addiction psychiatrist I have no interest in minimizing the risks of kratom or defending an inadequately regulated industry. My concern is that policy should be driven by pharmacology, clinical experience and measurable public health outcomes rather than blanket assumptions about an entire category of products. Rather than classifying all kratom as Schedule I, I encourage legislators to consider a comprehensive regulatory framework that includes:

  • Age restrictions: Individuals should be 21-plus years of age to purchase. 
  • Product testing: Require independent, third-party, laboratory testing for concentration limits, contaminants, adulterants and synthetic compounds. 
  • Transparent labelling: Require the disclosure of composition per serving and per container. 
  • Potency limits: Establish evidence-based limits on concentrated products.
  • Manufacturing standards: Require licensing, traceability and accountability throughout the entire supply chain. 
  • Targeted prohibitions: Restrict semi- and fully synthetic “kratom” products and products blended or adulterated with other constituents. 
  • Ongoing surveillance: Periodically track poison-control-related exposures, emergency department visits and other public health outcomes to determine whether the framework is working. 

New Hampshire has an opportunity to develop a policy that acknowledges risks, potential benefits and protects consumers, while holding manufacturers accountable without automatically criminalizing every product labeled as “kratom.” 

There are plenty of other options other than an unregulated marketplace or a blanket prohibition, and these involve thoughtful, evidence-informed regulation that can be longitudinally evaluated and refined as better data become available.

📄 Contenido indexado automáticamente. No es de autoría de altabusqueda.com; los derechos pertenecen a su fuente: New Hampshire Bulletin.
Ver nota original ↗
🤖 Profundizá esta noticia con OIMA (IA)

¿Querés un resumen rápido de esta noticia, hecho por nuestra IA?

Respuestas de OIMA · IA, sobre esta noticia · Abrir OIMA Chat ↗
💬 0

Comentarios

También te puede interesar

New Hampshire housing market is stagnating. Some see a silver lining
New Hampshire Bulletin
When New Hampshire’s housing market was at its hottest in recent years, the conversation Josh Greenwald might…
With dams across NH in disrepair, leaders disagree on where to focus
New Hampshire Bulletin
New Hampshire’s aging dams have environmentalists and safety experts wringing their hands. But disagreements …
With their new legislative majorities, NH Democrats eye education changes
New Hampshire Bulletin
When the New Hampshire Supreme Court found New Hampshire’s school funding unconstitutionally low in 2025, its…
More than ABCs: How students are falling behind before they enter kindergarten
New Hampshire Bulletin
The foundation for a child’s lifetime of learning is built from birth to age 5. By the time they reach kinder…
NH House Democrats nominate Simpson to be next speaker ahead of Dec. 2 vote
New Hampshire Bulletin
Rep. Alexis Simpson, who has led the New Hampshire House Democrats as minority leader for two years, is the c…
Commentary: What are key challenges facing New Hampshire as we head into 2027?
New Hampshire Bulletin
From rising housing, childcare and healthcare costs to a labor force with many workers reaching retirement ag…